ESMO 2026 | VANCE: plasma EBV DNA dynamics in NPC treated with EBV-specific CTL therapy
Han Chong Toh, MD, National Cancer Centre Singapore, Singapore, comments on an analysis of plasma Epstein-Barr virus (EBV) DNA dynamics in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) from the Phase III VANCE trial (NCT02578641), which compared gemcitabine and carboplatin with or without EBV-specific cytotoxic T lymphocyte (CTL) therapy. EBV DNA levels and trajectories were strongly prognostic for overall survival. The baseline-to-end-of-chemotherapy trajectory emerged as a potential predictive biomarker for CTL therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
